Number at risk Bivalirudin Heparin + GPIIb/IIIa Primary Endpoint Major Bleeding (%) Primary Endpoint Major Bleeding (%) Time in Days 8.4% 5.0% HR [95%CI] = 0.59 [0.45, 0.76] P< HR [95%CI] = 0.59 [0.45, 0.76] P< Heparin + GPIIb/IIIa inhibitor (n=1802) Bivalirudin monotherapy (n=1800) 30 Day Major Bleeding (non-CABG)